INTRODUCTION
Obesity and diabetes (DM) are common disorders that increase cardiometabolic risk and can lead to cardiovascular (CV) diseases [1] . Precise evaluation of obesity and DM-related CV risk depends on the quantity, distribution and location of body fat and the function of adipocytes in the total body and fat depots [2, 3] . Epicardial fat (EF), paracardial fat (PF) and perivascular fat (PVF) are specific visceral fat depots whose role in CV diseases is well established [4] . Epicardial fat is embryologically different from other depots; it has no anatomical boundaries with the heart muscle or coronary arteries [4] . Recent studies have suggested its active paracrine and endocrine role in coronary artery disease (CAD) [5] [6] [7] . The pathophysiological mechanisms responsible for the balance between protective and proatherosclerotic effects of EF are also not yet understood. Therefore, we aimed to evaluate the link between EF and PF volumes (EFV, PFV), relative expressions of several genes in EF, PF and PVF and corresponding serum cytokines in patients with multivessel CAD in relation to DM. We hypothesized that EF, PF and PVF samples obtained in patients with DM would have a more proatherogenic profile of genes expressions, which would be associated with serum cytokines and increased fat volumes.
PATIENTS AND METHODS

Study population
Sixty-six consecutive patients (age: 45-80 years old) with multivessel CAD scheduled for elective coronary artery bypass grafting (CABG) in the Department of Cardiac Surgery were finally included in the study after consideration of exclusion criteria. Given the aim of the study, the main exclusion criteria were as follows: acute coronary syndrome at the index hospitalization and in prior 6 months, prior thorax surgery, indications for any other type of cardiac surgery, significant heart valve dysfunction, congestive heart failure, left or right ventricle systolic dysfunction, significant diastolic dysfunction, infectious diseases in prior 2 months, chronic inflammatory diseases, neoplastic diseases (diagnosis and/or treatment in prior 5 years), significant renal or liver dysfunction, any anti-inflammatory or anti-infective medicines in prior month, secondary causes of obesity, specific interventions aimed at obesity in prior 12 months, a 10% unintentional weight loss in prior 3 months or risk of malnutrition (Mini Nutritional Assessment score < 12 points) [8] , a very poor image quality or contraindications to cardiac magnetic resonance (CMR), known genetic predisposition for CV diseases.
Study protocol
The study protocol included: a detailed clinical assessment (Table S1 ) with anthropometric parameters and adiposity, CMR performed for the volumetry of fat depots, peripheral venous blood samples for serum levels of cytokines and fat samples obtained during cardiac surgery.
Subjects were recruited and completed the study at the Department of Cardiology at the Medical University of Silesia. The study protocol was approved by the local Medical University of Silesia Ethic Committee (KNW/0022/KB1/127/I/13/14) and all patients gave their written informed consent to the protocol. This work was supported by the research noncommercial grant from Medical University of Silesia (KNW-1-085/N/5/0, KNW-1-016/K/8/K) and Polish Cardiac Society (Servier 2016).
Clinical characteristics
Hyperlipidemia, hypertension, DM and metabolic syndrome were identified based on prior diagnosis or current treatment and defined according to the guidelines [9] . Overweight and obesity were classified according to body mass index (BMI=body mass (kg) / height(m)²) as normal weight (18.5-24 .9kg/m²), overweight (25.0-29.9kg/m²) and obesity (30.0 kg/m²): class 1 (30.0-34.9 kg/m²), class 2 (35.0-39.9 kg/m²) and class 3 (40.0 kg/m²). Waist circumference (WC: midpoint between the lowest rib and the iliac crest) was measured with a tape at the end of expiration. Additional measures were also obtained: neck circumference just below the laryngeal prominence, midpoint thigh circumference and midpoint arm circumference and the sum of three parameters was calculated. Skinfolds measured the thickness of skin and subcutaneous fat as described by Jackson and Pollock [10] . The bioelectric impedance analysis (Bodystat 1500, Bodystat, Isle of Man, UK) was used to measure the patients' body composition with body fat percentage (BF%).
We used ultrasound (3.5MHz transducer, GE Vivid 9, Milwaukee, USA) in all patients to obtain the index measure of visceral abdominal fat [11] . All participants completed a detailed dietary assessment with a country-specific, validated food frequency questionnaire [12] .
Afterwards, it was converted into nutrients with a country-specific database used in the multicenter clinical study PURE [13] .
Cardiac magnetic resonance imaging of epicardial and paracardial fat
We quantified EF and PF volumes on ecg-gated cine images acquired on 1.5T system (GE Optima MR450w, GE Healthcare, Wisconsin, USA) with a dedicated cardiac coil using a steady-state free precession sequence. The scan parameters used were TE/TR (time to echo/time of repetition) 1.9/4.3 ms, slice thickness 8 mm (no inter-slice gap). EF and PF were defined as the particular adipose tissue in end-diastole (EFbetween myocardium and visceral layer of pericardium and PFall the fat surrounding the heart outside the EF) along the walls of the right and left ventricles starting from the basal segments (atrioventricular valves level) up to the apex area.
Adipose tissue areas were traced manually using short-axis images on the zoomed images proceeding through the slices from the atrioventricular valves to the LV apex and were multiplied by the slice thickness ( Figure S1 ). Afterwards, EF and PF volumes were calculated using the summation of disc method.
Blood collection
Blood samples were collected from all the patients prior to cardiac surgery. Afterwards, serum was obtained by centrifugation and the samples were stored in aliquots at -80 °C. The serum concentrations of the following cytokines (ELISA kits) were performed according to the manufacturer's protocols: Proadrenomedullin (ADM, Cucabio Biotech Co, Houston, USA), 
Adipose tissue collection
The adipose tissue samples were taken in the beginning of CABG procedure in tissues, which had not been previously traumatized. All fat samples were taken in the same order and locations in all patients: subcutaneous fat at sternotomy (1), PF within thorax (2), PVF from internal mammary artery (3) and EF adjacent to the proximal right coronary artery (4)( Figure   S2 ). The biopsy specimens were immediately stored at -80 °C until further analysis.
RNA extraction and Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
RNA was extracted using the phenol-chloroform method using TRI Reagent (MRC Inc, Cincinnati, USA) [14] . Adipose tissue samples (200mg each) were put into 2ml
Eppendorf-type tube directly into a 1 ml of TRI reagent, which contained 5μl of Precipitation carrier reagent (MRC Inc, Cincinnati, USA). Thereafter, samples were homogenized by means of a rotor/stator, hand-held homogenizer (IKA-Werke GmbH & Co KG, Staufen, Germany). All subsequent steps were performed according to the manufacturer's instruction.
Finally, purified RNA was resolved in 100μl of nuclease-free water. RNA concentration was determined spectrophotometrically by measuring the absorbance at 260 nm (BioPhotometer, Eppendorf). A 500ng of total RNA was reverse transcribed using High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Warsaw, Poland) in a reaction volume of 20μl. Finally, the reverse transcription reaction mixture was diluted 1:4 with nuclease-free water. Quantitative analysis of the above listed genes was carried out by two-step reverse transcription real-time quantitative PCR assay (real time QPCR). Human glyceraldehyde 3phosphate dehydrogenase gene (GAPDH) was used as a reference for quantitative analysis.
An amount of 2μl of the reverse transcription reaction mixture (i.e., an equivalent of 10 ng of total RNA) was used as a template for QPCR. Real-time QPCR was performed using SYBR Select Master Mix (Thermo Fisher Scientific, Warsaw, Poland) in a total volume of 20 μl that contained 200 nM of each (forward and reverse) gene-specific primers. All primers for QPCR were derived from PrimerBank database (https://pga.mgh.harvard.edu/primerbank/) [15] . All primer pairs spanned the intron/exon boundary so this excluded the possibility of false-positive results from genomic DNA. Reactions were performed using Roche LightCycler 480 Instrument II (Roche Diagnostics, Warsaw, Poland) with a thermal profile set as follows: 94°C / 3 min then 35 cycles of 94°C / 30 sec, 58°C / 30 sec, 72°C / 45 sec. The specificity of each reaction was confirmed by melting-curve analysis. The increase in fluorescence was measured in real time and threshold cycle (CT) values were obtained. The target gene Ct (threshold cycle) number was normalized to the endogenous reference GAPDH and the formula 2 (-ΔΔCt) was used to calculate relative (to subcutaneous fat) gene expression [16] .
Statistical analysis
The results presented in the manuscript or tables are expressed as means (standard deviation) for normally distributed variables, medians (quartiles Q1-Q3) for not-normal distribution or number (percentage). The distribution was tested for the normality with the Kolmogorov-Smironov test. Baseline clinical parameters and the measures were compared between the subgroups using the t-tests for normally distributed continuous variable (Student's t-test); in case of not-normal distribution, the Mann-Whitney U test was used.
Associations between parameters were assessed using Pearson or Spearmen correlation analysis depending on the parametric or nonparametric distribution of variables. A value p<0.05 was considered statistically significant. Statistical analysis was undertaken using Statistica software (version 10.0, Stat Soft, PL)
RESULTS
Study group characteristics
Our study group included 66 patients (age: 65.6 (7.2) y.o.; males 76%) with preserved LV systolic function and a multivessel CAD scheduled for CABG. Patients clinical characteristics, adiposity, ultrasound and CMR indexes of fat depots are shown in the Table   S1 . In brief, the study patients revealed several CV risk factors, including hypertension and dyslipidemia in all individuals and the following: overweight (51%), obesity (38%), DM (50%), nicotinism (48%).
Diabetes and mutivessel coronary artery disease
The study group was divided into the subgroups with and without DM ( Table 1) . Patients with and without DM revealed a very similar clinical characteristics, which allowed us to search for any differences in the quantity of fat depots, local mRNA genes expressions and corresponding serum cytokines concentrations.
There were no differences in the prevalence of CV risk factors, diet, clinical parameters of obesity and fat depots, except for EF volume (EFV), which was increased in patients with DM (105.6 (38.5) vs 84 (29.2) ml, p=0.02) ( Table 1) .
Serum profile of atherogenic cytokines
Serum PLTP levels were significantly higher in patients with compared to patients without DM (18.2 (12.5-31.4) vs 12.9 (8.5-22) µg/ml, P=0.03). However, serum concentrations of the following cytokines were similar in both subgroups: ADM, FGF-21, TGF, THBS-1, UCP-1 ( Table 2) .
Relative mRNA genes expressions in epicardial, paracardial and perivascular fat depots
Patients with DM showed a significantly higher RAGE expression in EF (0.17 (0.06-1.48) vs 0.08 (0.02-0.24) a.u., P=0.03). Diabetes was also associated with increased expression of Table 2) .
Given that patients with DM had significantly increased EF depot (EFV), all the relative expressions of genes obtained in the EF samples were indexed to EFV and compared (Table   3) . p=0.04). The CMR quantity parameters of fat depots did not reveal associations with serum cytokines or mRNA expressions in corresponding fat depots.
There were significant associations of relative expressions of FGF-21, RAGE or ADM in different fat depots (Table S2 ).
All other associations not mentioned above, including genes expressions of all three fat depots and the corresponding cytokines serum concentrations were not significant (data not shown). To the best of our knowledge, this is the first study providing a comprehensive CMR assessment and profile of genes expressions in three fat depots with serum concentrations of corresponding cytokines in multivessel CAD suggesting a unique pathophysiological findings for DM.
DISCUSSION
FAT DEPOTS QUANTITY
In our study, patients with multivessel CAD and DM showed significantly increased EF compared to non-DM individuals, which is in line with previous reports [17, 18, 19] . None of the other fat depots or anthropometric parameters of obesity revealed any differences between both subgroups. There are several studies, which were focused on histological analysis of fat samples obtained mainly in larger visceral fat depots or individuals with severe obesity in relation to obesity or metabolic dysfunction [20] [21] [22] . Increased EFV results from various depot-specific histological findings, including a simple hypertrophy and hyperplasia in response to excess energy in obesity to inflammatory cells infiltration and different patterns of fibrosis in DM and dyslipidemia [21] . The increase in adiposity is associated with enhanced inflammation [22] and adipocyte size and distribution is also linked with insulin resistance and DM, but evidence regarding causative associations is limited [23] . Our study patients represented various BMI categories and some EF samples obtained from lean subjects were not enough for additional histological study. EFV showed only moderate associations with BMI and WC and a moderate association with serum TGF, which was found in all patients.
Moreover EFV was inversely correlated with UCP-1 expression, especially in patients with DM. It suggests, that the increased quantity of EF is more specific for metabolic disturbances, including DM and not related to serum cytokines or mRNA genes expression involved in atherogenesis. UCP-1 is a major marker of brown adipose tissue (BAT), which is also involved in rapid thermogenesis and it was also found in EF among adults [24] . Our results showed no differences in UCP-1 expression in EF between patients with and without DM, which suggests that there is no difference in BAT-like phenotype in DM [25] . An inverse relation between EF expression of UCP-1 and EFV may be a result of a simple compensatory mechanism driven by a demand for thermogenesis [24] . However, evidence on UCP-1 expression in EF in relation to risk factors and EFV is ambiguous. Sacks et al showed no significant association between UCP-1 expression and EFV or DM [26] .
EPICARDIAL FAT GENES EXPRESSIONS
Epicardial fat is a unique depot with several local and systemic effects [2] . We aimed to assess the associations between various pro-and antiatherogenic cytokines with the most limited evidence in previous studies [4] . Our study is the first to show that FGF-21 expression in visceral fat depots of patients with multivessel CAD and DM is significantly lower compared to non-DM individuals. Decreased expression of FGF-21 was found in EF and PF depots, which suggests that the lower expression of cardioprotective cytokine is a specific finding for DM, but not limited to epicardial (=pericoronary) fat as it is also found in other visceral fat depot. There were no differences in serum levels of FGF-21 between patients with and without DM. Our finding suggest that future clinical trials aimed at FGF-21 therapy should be focused on that subgroup of patients.
Fibroblast Growth Factors are a family of cytokines with multiple intracellular, paracrine and endocrine effects on cardiovascular system and metabolic pathways. FGF 21 is a new and the most promising cytokine in this family due to suggested cardioprotective role in CV diseases, including atherosclerosis [27] . FGF-21 serum levels were found to be increased in obesity, DM, metabolic syndrome, dyslipidemia, non-alcoholic fatty liver disease and coronary or peripheral artery disease [28] . Researchers speculate that increased serum levels of FGF-21 may be an early biomarker of cardiometabolic dysfunction or it may reflect a compensatory cardioprotective response in pathological states [28] . Moreover, a growing body of evidence suggests that FGF-21 is not only a CV marker, but it plays some cardioprotective role. FGF-21 was shown to exert lipid-lowering effects [29] , anti-atherosclerotic effects [31] and cardioprotection in myocardial ischemia/reperfusion injury [32] . Moreover, a long-term treatment of FGF-21 was shown to prevent diabetic cardiomyopathy [33] . Although liver is a major producer of serum FGF-21, FGF-21 pathways were also evidenced in adipose tissue [34] where it improves glucose uptake, lipolysis, oxidative capacity and it affects thermogenic activity of BAT [35] . The evidence supporting CV and metabolic protective effects encouraged researchers to test the exogenous FGF-21 in animal models and therapy in humans in clinical trials [36, 37] .
RAGE is a multiligand receptor for advanced glycation endproducts and other peptides, which is involved in the inflammatory process, metabolic dysfunction and atherosclerosis [38] . We found that patients with DM have significantly increased expression of RAGE in EF with no differences in PF and PVF depots compared to non-DM individuals. Epicardial RAGE expression was not associated with the amount of epicardial depot as it was reported by Dozio et al [38] using echocardiography fat thickness. However, we used a reference method of CMR providing EFV, which is a much more precise parameter. RAGE may be involved In atherosclerosis in both DM and non-DM conditions [39, 40] , but our results suggest that it is associated with several proatherogenic pathways only in patients with multivessel CAD and DM.
ADM was shown to exert some protective effects on cardiac ischemia/reperfusion injury, vascular calcification or inflammation, it is also involved in obesity-related insulin resistance in experimental models [41] . Iacobellis et al showed that ADM mRNA expression in EF was lower in patients with CAD than in non-CAD patients [42] . Our study group included only patients with multivessel CAD and we found that ADM expression is upregulated in individuals with DM suggesting a compensatory mechanism. Alternatively, lower expression of protective ADM observed in patients with DM may be more pronounced in non-DM individuals.
There were no differences between patients with and without DM in mRNA expressions of TGF, PLTP, THSB-1 and UCP-1. It suggests that those cytokines are not unique for coronary atherosclerosis in DM.
QUALITY AND FUNCTION OF EPICARDIAL FAT
Although all study patients had a multivessel CAD, those with DM revealed a more proatherogenic profile of fat genes expressions suggesting that a pericoronary fat dysfunction may play more important role in this subgroup. Our study protocol involved CMR as a reference method for EF quantification and other imaging methods, including echocardiography may provide only an approximate measure of EF. Finally, we show that except for UCP-1, none of the other genes expression was related to EFV. However, relative expressions of genes in EF were not different (except for tendency for ADM) between both subgroups when indexed to EFV. It implies that the differences in expressions of most genes found in patients with DM may be interrelated with the amount of EF.
Moreover, we also found that serum levels of cytokines involved in atherogenesis do not reflect their expressions in EF and serum concentrations cannot be used as simple markers of fat dysfunction. While pro and anti-atherogenic cytokines assessed in serum may reflect systemic or metabolic dysfunction, EF genes profile may reflect local fat dysfunction, which is a more important link between DM and multivessel CAD. Diet nutrients obtained with a very detailed PURE questionnaire were not associated with EF function.
LIMITATIONS
Our results are based on a cross-sectional study and thus we cannot draw conclusions on causality and prospective changes in fat depots. However, our study design and methods used for fat specimens assessment are limited to cardiac surgery, which makes prospective observation nearly impossible. For the same reasons, we also do not compare our result with control healthy group as we believe that other clinical indications for cardiac surgery are always associated with some alterations in cytokines serum levels or genes expressions.
Moreover, unlike previous studies, we compared and correlated serum concentrations and local genes expressions of corresponding cytokines and reference volumes of fat depots, including PVF around IMA. However, due to difficulty and safety in obtaining EF specimens, the volume of specimens, especially in lean non-DM individuals hindered assessment of genes at the protein levels or histological analysis.
CONCLUSIONS AND CLINICAL IMPLICATIONS
Increasing prevalence of obesity, DM and related adipose tissue dysfunction will be important trigger for CV diseases. Among patients with multivessel CAD, DM is associated with increased EFV and more dysfunctional profile of genes expression in EF. The amount of EF Gene mRNA expression in particular fat depot relative to its expression in subcutaneous fat (for details see methods). All values in arbitrary units (a.u.). 
